ACP3

Across TCGA pan-cancer cohorts, ACP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACP3 data layer compared with 19 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher ACP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACP3 expression acts as an unfavorable survival marker.

READ, ESCA, and PRAD are the cancer types where ACP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.054	0.920	<.001	18	view →
ESCA	DFS	Median	All	0.147	0.536	.005	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ACP3–READ (OS)

Open the READ breakdown →